Drug Profile

Research programme: neuropsychiatric disorder therapies - Neumora Therapeutics/Vanderbilt University

Latest Information Update: 26 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vanderbilt University
Developer Neumora Therapeutics; Vanderbilt University
Class Neuropsychotherapeutics; Small molecules
Mechanism of Action Muscarinic M4 receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Neurological disorders; Psychiatric disorders; Schizophrenia

Most Recent Events

12 May 2025 Neumora Therapeutics plans a clinical trial for Neuropsychiatric disorders in mid-2025
15 Apr 2024 Neumora Therapeutics announces intention to submit IND in first half of 2025
17 Feb 2022 Neumora Therapeutics in-licenses neuropsychiatric disorders therapies from Vanderbilt University

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com